Skip to Main Content

Paper Details

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Leukemia
141
2019
Author NameAffiliation
Daniel A PollyeaUniversity of Colorado School of Medicine
Martin S TallmanMemorial Sloan Kettering Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Robert H CollinsUT Southwestern Medical Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2